(Q38001940)

26 August 2017

title

Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target (English)

1 reference

26 August 2017

Yan Jia

1

1 reference

26 August 2017

Vitaly Polunovsky

series ordinal

2

1 reference

26 August 2017

Peter B Bitterman

series ordinal

3

1 reference

26 August 2017

Carston R Wagner

series ordinal

4

1 reference

26 August 2017

publication date

11 April 2012

1 reference

Medicinal Research Reviews

26 August 2017

published in

1 reference

26 August 2017

volume

32

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

786-814

1 reference

Reconfiguration of yeast 40S ribosomal subunit domains by the translation initiation multifactor complex.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Cap-dependent and cap-independent translation in eukaryotic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Protein synthesis in eukaryotes: the growing biological relevance of cap-independent translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Image analysis of Artemia salina ribosomes by scanning transmission electron microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Protein-protein interactions required during translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The plant translational apparatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

A tale of two termini: a functional interaction between the termini of an mRNA is a prerequisite for efficient translation initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The cap-dependent translation apparatus integrates and amplifies cancer pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

eIF-4E expression and its role in malignancies and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

eIF4E expression in tumors: its possible role in progression of malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Targeting the eukaryotic translation initiation factor 4E for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Translation initiation and its deregulation during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

eIF4E activity is regulated at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

mTOR signaling: implications for cancer and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Cap-independent regulation of gene expression in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Re-programming of translation following cell stress allows IRES-mediated translation to predominate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Translational control in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

MNK, EIF4E and targeting translation for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Dissecting eIF4E action in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Structural basis for mRNA Cap-Binding regulation of eukaryotic initiation factor 4E by 4E-binding protein, studied by spectroscopic, X-ray crystal structural, and molecular dynamics simulation methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Phylogenetic analysis of eIF4E-family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Structures of the human eIF4E homologous protein, h4EHP, in its m7GTP-bound and unliganded forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Characterization of mammalian eIF4E-family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: evidence for a one-step binding mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Kinetic mechanism for assembly of the m7GpppG.eIF4E.eIF4G complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Influence of electric charge variation at residues 209 and 159 on the interaction of eIF4E with the mRNA 5' terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Wheat germ initiation factors 4F and (iso)4F interact differently with oligoribonucleotide analogues of rabbit alpha-globin mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

A fluorescence study of the interaction of protein synthesis initiation factors 4A, 4E, and 4F with mRNA and oligonucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Novel "anti-reverse" cap analogs with superior translational properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

A mutant of eukaryotic protein synthesis initiation factor eIF4E(K119A) has an increased binding affinity for both m7G cap analogues and eIF4G peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Ribosome loading onto the mRNA cap is driven by conformational coupling between eIF4G and eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Cooperative modulation by eIF4G of eIF4E-binding to the mRNA 5' cap in yeast involves a site partially shared by p20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5'-Cap by domains of eIF4G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Inhibition of eukaryotic translation by nucleoside 5'-monophosphate analogues of mRNA 5'-cap: changes in N7 substituent affect analogue activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Inhibition of eukaryotic translation by analogues of messenger RNA 5'-cap: chemical and biological consequences of 5'-phosphate modifications of 7-methylguanosine 5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Antiviral nucleoside drug delivery via amino acid phosphoramidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Pharmacokinetics of amino acid phosphoramidate monoesters of zidovudine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Identification and expression analysis of genes associated with bovine blastocyst formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact.

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2FMED.21260

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Mechanisms of action of ribavirin in antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The role of ribavirin in the combination therapy of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The relationship between the metabolism of ribavirin and its proposed mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The metabolism of ribavirin in erythrocytes and nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

RNA virus error catastrophe: direct molecular test by using ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The broad spectrum antiviral agent ribavirin inhibits capping of mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Further evidence that ribavirin interacts with eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Specific, efficient, and selective inhibition of prokaryotic translation initiation by a novel peptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Targeting death receptors in cancer with Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Translational regulation of TRAIL sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

DEAD-box proteins: the driving forces behind RNA metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Antisense oligonucleotide-based therapeutics for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Progress in antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMED.21260

Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Positive Heat Capacity Change upon Specific Binding of Translation Initiation Factor eIF4E to mRNA 5‘ Cap†

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Stopped-flow and Brownian dynamics studies of electrostatic effects in the kinetics of binding of 7-methyl-GpppG to the protein eIF4E

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Effects of pH on kinetics of binding of mRNA-cap analogs by translation initiation factor eIF4E.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

A spectroscopic study of the binding of m7GTP and m7GpppG to human protein synthesis initiation factor 4E

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Crystal structures of 7-methylguanosine 5'-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5',5'-triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible reg

1 reference

https://pubmed.ncbi.nlm.nih.gov/22495651

12 December 2020

Identifiers

DOI

10.1002/MED.21260

1 reference

26 August 2017

0 references

1 reference